期刊
LEUKEMIA
卷 25, 期 1, 页码 110-120出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2010.231
关键词
'5q-syndrome'; cytogenetics; deletion 5q; myelodysplastic syndromes
资金
- Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo, Spain [FI07/00107, CA08/00141, PI07/1009]
- Red Tematica de Investigacion Cooperativa en Cancer (RTICC and FEDER) [RD06/0020/0031, RD07/0020/2004]
- European Leukemia Net
- National Institutes of Health (NIH) [5PO11CA108631]
- Myelodysplastic Syndromes Foundation
- NATIONAL CANCER INSTITUTE [P30CA016672, P01CA108631] Funding Source: NIH RePORTER
This cooperative study assessed prognostic factors for overall survival (OS) and risk of transformation to acute myeloid leukemia (AML) in 541 patients with de novo myelodysplastic syndrome (MDS) and deletion 5q. Additional chromosomal abnormalities were strongly related to different patients' characteristics. In multivariate analysis, the most important predictors of both OS and AML transformation risk were number of chromosomal abnormalities (P<0.001 for both outcomes), platelet count (P<0.001 and P = 0.001, respectively) and proportion of bone marrow blasts (P<0.001 and P = 0.016, respectively). The number of chromosomal abnormalities defined three risk categories for AML transformation (del(5q), del(5q) + 1 and del(5q) + >= 2 abnormalities) and two for OS (one group: del(5q) and del(5q) + 1; and del(5q) + >= 2 abnormalities, as the other one); with a median survival time of 58.0 and 6.8 months, respectively. Platelet count (P = 0.001) and age (P = 0.034) predicted OS in patients with '5q-syndrome'. This study demonstrates the importance of additional chromosomal abnormalities in MDS patients with deletion 5q, challenges the current '5q-syndrome' definition and constitutes a useful reference series to properly analyze the results of clinical trials in these patients. Leukemia (2011) 25, 110-120; doi: 10.1038/leu.2010.231; published online 30 September 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据